Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge
The antibody was designed and developed at Abzena’s Cambridge, UK,
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Subscribe To Our Newsletter & Stay Updated
